Nektar Therapeutics (NASDAQ:NKTR) announced today that it has received a $100 million payment under a license agreement with AstraZeneca. The cash payment under the Nektar-AstraZeneca …
Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca announced that MOVANTIK™ (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) …
Brean Capital analyst Jonathan Aschoff weighed in today with a few insights on Nektar Therapeutics (NASDAQ:NKTR), following the news that AstraZeneca plc (ADR) (NYSE:AZN) will commercialize Movantik in the US jointly …
Brean Capital analyst Jonathan Aschoff came out today with a research note on Nektar Therapeutics (NASDAQ:NKTR), reducing the price target to $17 (from $20) and …
Piper Jaffray analyst Joshua Schimmer came out with a research note on Nektar Therapeutics (NASDAQ:NKTR), following the company’s fourth-quarter results posting revenue of $19.5 million compared to Jaffray’s estimate …
Brean Capital analyst Jonathan Aschoff was out pounding the table on Nektar Therapeutics (NASDAQ:NKTR) Wednesday, reiterating a Buy rating and a price target …
Nektar Therapeutics (NASDAQ:NKTR) announced the enrollment of the first patient in SUMMIT-07, its initial Phase 3 study of NKTR-181, a first-in-class, opioid analgesic molecule with …
Roth Capital analyst Debjit Chattopadhyay weighed in on Nektar Therapeutics (NASDAQ:NKTR), as the company will announce its financial results for the fourth-quarter on February 24, 2015. The …
In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a …